

**Seroprevalence of mumps IgG antibodies in healthcare workers in 2018.** The circles denote the mean seropositivity rate (%) and error bars denote 95% confidence intervals (CI), and the dashed line denotes 75% and 86% seropositivity rates.




Fig. 1.

finding, we recommend that MMR vaccination after serologic testing may be a more reasonable approach than universal MMR vaccination alone in Korea.

**Funding:** None

**Disclosures:** None

Doi:10.1017/ice.2020.1023

#### Presentation Type:

Poster Presentation

#### Sherlock Holmes: Whose Tissue Is It Anyway?

Bonita Lee, University of Alberta; Jason Silverman, University of Alberta; Atilano Lacson, Alberta Health Services; Iyare Izevbaye, University of Alberta Hospital; Hien Huynh, Department of pediatrics, University of Alberta; Consolato Sergi, University of Alberta; Remegio Maglantay, University of Alberta Hospital; Cheryl Mather, Alberta Precision Laboratories Ltd.; Adrian Box, Alberta Health Services; Teresa Paonessa, Alberta Health Services; Rebecca Nawaz, Alberta Health Services; Jesusa Pulongbarit, Alberta Health Services; Mario Tremblay, Alberta Health Services; Kathy VanVeen, Alberta Health Services; Joan Durand, Alberta Health Services; Melody Cordoviz, Alberta Health Services; Nancy Aelick, Alberta Health Services; Catherine Williamson, Alberta Health Services

**Background:** The medical device reprocessing department (MDRD) is a crucial patient safety area with checkpoints to ensure appropriate reprocessing. **Objective:** We report the application of molecular pathology in the investigation of potential blood and body fluid exposure (BBFE) during endoscopy. **Methods:** When there is a potential BBFE from a medical device, our hospital

has a systematic process whereby the clinical area involves the MDRD and the infection prevention control (IPC) team. The MDRD provides reprocessing documentation, including detailed information regarding the prior use of the devices. The clinician and the IPC physician discuss the risk of BBFE. If patient disclosure occurs, the IPC physician provides follow-up as appropriate. This report illustrates the collaboration of clinicians, the IPC team, the MDRD, pathologists, and molecular pathologists in investigating the possibility of residual human tissue and BBFE during endoscopy. **Case reports:** Two independent but similar events occurred in September 2016 and September 2019 in the pediatric endoscopy suite at our site, a tertiary-care pediatric hospital with 163 beds in Edmonton, Canada. During both endoscopies, the pediatric gastroenterologists observed a piece of tissue ejected from the gastro-scope into the intestinal lumen when the biopsy forceps were pushed out of the channel for the first time. This observation raised concerns of possible gaps in the reprocessing of the endoscope and residual tissue remaining in the working channel after its last use. Both gastroenterologists were able to retrieve the presumed foreign tissue; however, both patients had possible BBFE because the mucosal surface was breached by the biopsy forceps. The MDRD reprocessing of both endoscopes was reviewed, and no gap was identified. In discussion with the pathologists and molecular pathologists, human identity testing using genetic markers was performed on the biopsy blocks of the previous patient on whom the endoscope was used, the potentially exposed patient, and the presumed foreign tissue for each event. The test results indicated that the presumed foreign tissue was in fact from the potentially exposed patient and therefore there was no BBFE. It is presumed that the working channel itself captured a small amount of the

patient's tissue during scope insertion. The results were a relief to the patients and families. **Conclusions:** It is prudent to investigate residual foreign tissue in a medical device that is being used on patients with mucosal breaches. Molecular pathology involving human identity testing is a very useful tool in the investigation of these types of events.

**Funding:** None

**Disclosures:** None

Doi:10.1017/ice.2020.1024

**Presentation Type:**

Poster Presentation

**Shifting Landscape of Healthcare-Associated Infection and Antimicrobial Resistant Infection Reporting Policy, 2005–2019**

Jeremy Goodman, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Samuel Clasp, Population Health and Healthcare Office, Office of the Associate Director for Policy and Strategy, CDC; Arjun Srinivasan, Centers for Disease Control and Prevention; Elizabeth Mothershed, Centers for Disease Control and Prevention; Seth Kroop, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Lyn Nguyen, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; Tara Holiday, Centers for Disease Control and Prevention

**Background:** Healthcare-associated infections (HAIs) are a serious threat to patient safety; they account for substantial morbidity, mortality, and healthcare costs. Healthcare practices, such as inappropriate use of antimicrobials, can also amplify the problem of antimicrobial resistance. Data collected to target HAI prevention and antimicrobial stewardship efforts and measure progress are an important resource for assuring transparency and accountability in healthcare, tracking adverse outcomes, investigating healthcare practices that may spread or protect against disease, detecting and responding to the spread of resistant pathogens, preventing infections, and saving lives. **Methods:** We discuss 3 healthcare-associated infection and antimicrobial Resistant infection (HAI-AR) reporting types: NHSN HAI-AR reporting, reportable diseases, and nationally notifiable diseases. HAI-AR reporting requirements outline facilities and data to report to NHSN and the health department to comply with state laws. Reportable diseases are those that facilities, providers, and laboratories are required to report to the health department. Nationally notifiable diseases are those reported by health departments to the CDC for nationwide surveillance and analysis as determined by Council of State and Territorial Epidemiologists (CSTE) and the CDC. Data presented are based on state and federal policy; NHSN data are based on CDC reporting statistics. **Results:** Since the 2005 launch of the CDC NHSN and publication of federal advisory committee HAI reporting guidance, most states have established policies stipulating healthcare facilities in their jurisdiction report HAIs and resistant infections to the NHSN to gain access to those data, increasing from 2 states in 2005, to 18 in 2010, and to 36 states, Washington, DC, and Philadelphia in 2019. Reporting policies and NHSN participation expanded greatly following the 2011 inception of CMS HAI quality reporting requirements, with several states aligning state requirements with CMS reporting. States listing carbapenem-resistant Enterobacteriaceae (CRE) as a reportable disease increased from 7 in 2013 to 41 states and the District of Columbia in 2019. Vancomycin-intermediate and




Fig. 1.

**NHSN Extension of Coverage**

Facilities Reporting to NHSN and CMS Reporting Requirement Start Dates




Fig. 2.

vancomycin-resistant *Staphylococcus aureus* (VISA/VRSA) was added as a nationally notifiable disease in 2004, carbapenemase-producing CRE (CP-CRE) was added in 2018, and *Candida auris* clinical infections were added in 2019. The CDC and most jurisdictions with HAI reporting mandates issue public reports based on aggregate state data and/or facility-level data. States may also alert healthcare providers and health departments of emerging threats and to assist in notifying patients of potential exposure. **Conclusions:** Through efforts by health departments, facilities, patient advocates, partners, the CDC, and other federal agencies, HAI-AR reporting has steadily increased. Although reporting laws and data uses vary between jurisdictions, data provided serves as valuable tools to inform prevention.

**Funding:** None

**Disclosures:** None

Doi:10.1017/ice.2020.1025

**Presentation Type:**

Poster Presentation

**Site Visits Reveal Common Gaps in Instrument Reprocessing and Sterilization at Philadelphia Dental Clinics**

Tiina Peritz, Philadelphia Department of Public Health; Susy Rettig; Susan Coffin, Children's Hospital of Philadelphia

**Background:** Most dental clinics lack resources and oversight related to infection prevention and control (IPC) practices. Few dental clinics undergo inspections by regulatory authorities unless